Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia

K. P. Grootens; N. M.J. van Veelen; M. M. Sitskoorn; B. G.C. Sabbe; J. Peuskens; J. K. Buitelaar; R. J. Verkes; R. S. Kahn

doi:10.1016/j.euroneuro.2010.08.003

Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia

K. P. Grootens
, N. M.J. van Veelen
, M. M. Sitskoorn
, B. G.C. Sabbe
, J. Peuskens
, J. K. Buitelaar
, R. J. Verkes
, R. S. Kahn

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Introduction: To enhance functional outcome in schizophrenia improvement of cognitive symptoms is crucial. Experimental procedures: Using a comprehensive test battery, this follow-up examines cognitive effects in patients with recent-onset schizophrenia after a change of medication following insufficient clinical response and intolerance. Results: After eight weeks cognitive outcomes had not improved in the patients having switched from olanzapine to ziprasidone (n=11; mean dose 136 mg) nor in those having switched from ziprasidone to olanzapine (n=10; mean 16 mg), while the symptoms of patients maintaining olanzapine (n=18; mean 10.9 mg) or ziprasidone (n=18; mean 88.9 mg) treatment had not improved further. Discussion: The findings suggest that also in early-stage schizophrenia the antipsychotics tested affect cognitive symptoms similarly.

Original language	English
Pages (from-to)	907-912
Number of pages	6
Journal	European Neuropsychopharmacology
Volume	20
Issue number	12
DOIs	https://doi.org/10.1016/j.euroneuro.2010.08.003
State	Published - Dec 2010
Externally published	Yes

Keywords

Antipsychotics
Clinical trial
Schizophrenia

Access to Document

10.1016/j.euroneuro.2010.08.003

Cite this

@article{297db0e537a04bf99871620749a4cd62,

title = "Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia",

abstract = "Introduction: To enhance functional outcome in schizophrenia improvement of cognitive symptoms is crucial. Experimental procedures: Using a comprehensive test battery, this follow-up examines cognitive effects in patients with recent-onset schizophrenia after a change of medication following insufficient clinical response and intolerance. Results: After eight weeks cognitive outcomes had not improved in the patients having switched from olanzapine to ziprasidone (n=11; mean dose 136 mg) nor in those having switched from ziprasidone to olanzapine (n=10; mean 16 mg), while the symptoms of patients maintaining olanzapine (n=18; mean 10.9 mg) or ziprasidone (n=18; mean 88.9 mg) treatment had not improved further. Discussion: The findings suggest that also in early-stage schizophrenia the antipsychotics tested affect cognitive symptoms similarly.",

keywords = "Antipsychotics, Clinical trial, Schizophrenia",

author = "Grootens, \{K. P.\} and \{van Veelen\}, \{N. M.J.\} and Sitskoorn, \{M. M.\} and Sabbe, \{B. G.C.\} and J. Peuskens and Buitelaar, \{J. K.\} and Verkes, \{R. J.\} and Kahn, \{R. S.\}",

note = "Funding Information: This work was supported by Pfizer. Pfizer had no further role in the design of the study, the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. ",

year = "2010",

month = dec,

doi = "10.1016/j.euroneuro.2010.08.003",

language = "English",

volume = "20",

pages = "907--912",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier B.V.",

number = "12",

}

TY - JOUR

T1 - Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia

AU - Grootens, K. P.

AU - van Veelen, N. M.J.

AU - Sitskoorn, M. M.

AU - Sabbe, B. G.C.

AU - Peuskens, J.

AU - Buitelaar, J. K.

AU - Verkes, R. J.

AU - Kahn, R. S.

N1 - Funding Information: This work was supported by Pfizer. Pfizer had no further role in the design of the study, the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

PY - 2010/12

Y1 - 2010/12

N2 - Introduction: To enhance functional outcome in schizophrenia improvement of cognitive symptoms is crucial. Experimental procedures: Using a comprehensive test battery, this follow-up examines cognitive effects in patients with recent-onset schizophrenia after a change of medication following insufficient clinical response and intolerance. Results: After eight weeks cognitive outcomes had not improved in the patients having switched from olanzapine to ziprasidone (n=11; mean dose 136 mg) nor in those having switched from ziprasidone to olanzapine (n=10; mean 16 mg), while the symptoms of patients maintaining olanzapine (n=18; mean 10.9 mg) or ziprasidone (n=18; mean 88.9 mg) treatment had not improved further. Discussion: The findings suggest that also in early-stage schizophrenia the antipsychotics tested affect cognitive symptoms similarly.

AB - Introduction: To enhance functional outcome in schizophrenia improvement of cognitive symptoms is crucial. Experimental procedures: Using a comprehensive test battery, this follow-up examines cognitive effects in patients with recent-onset schizophrenia after a change of medication following insufficient clinical response and intolerance. Results: After eight weeks cognitive outcomes had not improved in the patients having switched from olanzapine to ziprasidone (n=11; mean dose 136 mg) nor in those having switched from ziprasidone to olanzapine (n=10; mean 16 mg), while the symptoms of patients maintaining olanzapine (n=18; mean 10.9 mg) or ziprasidone (n=18; mean 88.9 mg) treatment had not improved further. Discussion: The findings suggest that also in early-stage schizophrenia the antipsychotics tested affect cognitive symptoms similarly.

KW - Antipsychotics

KW - Clinical trial

KW - Schizophrenia

UR - https://www.scopus.com/pages/publications/77958194977

U2 - 10.1016/j.euroneuro.2010.08.003

DO - 10.1016/j.euroneuro.2010.08.003

M3 - Article

C2 - 20833514

AN - SCOPUS:77958194977

SN - 0924-977X

VL - 20

SP - 907

EP - 912

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

IS - 12

ER -

Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia

Abstract

Keywords

Access to Document

Fingerprint

Cite this